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CytokinesNon-steroidal anti-inﬂammatory drugs (NSAIDs) represent a group of approximately 50 different medicines
that are widely prescribed for the management of inﬂammation and that exhibit variable anti-inﬂammatory,
anti-pyretic and analgesic activities. Most NSAIDs also exhibit a shared set of adverse effects, particularly
related to gastrointestinal complications; thus, the development of new drugs for the treatment of chronic
inﬂammation and pain continues to be an issue of high interest. Hydantoin and indole derivatives are reported
to possess various pharmacological effects, including anti-inﬂammatory and analgesic activities. Therefore,
the aim of this study was to evaluate the potential anti-inﬂammatory and antinociceptive activities of hybrid
molecules containing imidazole and indole nuclei. The anti-inﬂammatory activities of 5-(1H-Indol-3-yl-
methylene)-2-thioxo-imidazolidin-4-one (LPSF/NN-56) and 3-(4-Bromo-benzyl)-5-(1H-indol-3-yl-methy-
lene)-2thioxo-imidazolidin-4-one (LPSF/NN-52) were evaluated using air pouch and carrageenan-induced
peritonitis models as well as an acetic acid-induced vascular permeability model followed by IL-1β and TNF-α
quantiﬁcation. To evaluate the antinociceptive activities of the compounds, acetic acid-induced nociception,
formalin and hot plate tests were also performed. The anti-inﬂammatory activities of the compounds were
evidenced by a reduction in both leukocyte migration and the release of TNF-α and IL-1β in air pouch and
peritonitis models. Upon acetic acid-induced nociception, a decrease in the level of abdominal writhing in the
groups treated with LPSF/NN-52 (52.1%) or LPSF/NN-56 (63.1%) was observed. However, in the hot plate test,
none of the derivatives tested exhibited an inhibition of nociception. These results indicate that the
compounds tested exhibited promising anti-inﬂammatory and antinociceptive activities that likely involved
the modulation of the immune system.ticos, Universidade Federal de
niversitária, Recife/PE, Brazil.
Gonçalves-Silva).
vier OA license.© 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Inﬂammation is an essential response to tissue injuries that occur
due to physical, chemical or biological insults. Both acute and chronic
inﬂammations play essential roles in the restoration of homeostasis
[1]. However, the mechanisms by which activated leukocytes combat
germs and tumor cells and eliminate tissue debris in areas of
inﬂammation lead to the production of oxidants and/or of cytotoxic
cytokines [2,3]. These processes are ﬁnely regulated but may oc-
casionally escape control and prolong the inﬂammatory response,
creating a self-perpetuating condition that produces further damage
to the injured tissue [4].The inﬂammatory cascade is characterized by an immediate initial
response,whereupon the detection of antigens and/or damage leads to
the recruitment of neutrophils to the site of insult via the action of
chemoattractant mediators; this is followed by the subsequent
invasion of monocytes/macrophages, which become the primary
immune cell type present after 48 h [5,6]. The activation of neutrophils
leads to the secretion of cytokines that amplify the inﬂammatory
response, resulting not only in lymphocyte inﬁltration, but also in
vascular changes, edema and enzymatic destruction. Granulocytes
migrate into the inﬂamed sites and promote the generation of
arachidonic acid metabolites and leukotrienes by lipoxins [7].
Non-steroidal anti-inﬂammatory drugs (NSAIDs) represent a group
of approximately 50 different medicines that are widely prescribed for
the management of pain and exhibit variable anti-inﬂammatory, anti-
pyretic and analgesic activities [8]. However, most NSAIDs also exhibit a
shared set of adverse effects, particularly with regard to gastrointestinal
complications; thus, the development of new drugs for the treatment of
chronic inﬂammation and pain continues to be an issue of high interest
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(GI) toxicities. The free –COOH group is responsible for the GI toxicity
associated with all traditional NSAIDs [10].
The hydantoins (imidazolidin-2,4-dione) are interesting com-
pounds due to their occurrence in nature, chemical reactivity (with
consequent afﬁnity for biomacromolecules) and numerous biological
properties that are favorable for drug development. Structural
changes in the imidazolidine ring of such compounds yieldsmolecules
with variety of pharmacological properties, including anti-inﬂamma-
tory, antifungal, antibacterial, hypoglycemic, schistosomicides and
anti-cancer activities, among others [11,12]. Therefore, the aim of this
study was to evaluate the potential anti-inﬂammatory and antinoci-
ceptive activities of hybrid indole–imidazolidines molecules.
2. Materials and methods
2.1. Drugs
5-(1H-Indol-3-yl-methylene)-2-thioxo-imidazolidin-4-one
(LPSF/NN-56) and 3-(4-Bromo-benzyl)-5-(1H-indol-3-yl-methylene)-
2-thioxo-imidazolidin-4-one LPSF/NN-52) were synthesized and pro-
vided by the Núcleo de Pesquisa em Inovação Terapêutica of
Universidade Federal de Pernambuco, Brazil. Fentanyl was purchased
from Cristália, São Paulo, Brazil. Dexamethasone and diclofenac were
purchased from Aché, São Paulo, Brazil. EDTA was purchased from
Labtest, São Paulo, Brazil. Mouse TNF-α and IL-1β ELISA kits were
purchased from eBioscience, São Paulo, Brazil. Glacial acetic acid was
purchased from VETEC, São Paulo, Brazil. Cremophor, carrageenan,
Evans blue and indomethacin were purchased from Sigma, USA. All
drugs were dissolved in saline, except for LPSF/NN-56 and LPSF/NN-52,
which were dissolved in saline containing 5% Cremophor.
2.2. Chemistry
5-(1H-Indol-3-yl-methylene)-2-thioxo-imidazolidin-4-one (LPSF/
NN-56) and 3-(4-Bromo-benzyl)-5-(1H-indol-3-yl-methylene)-2-
thioxo-imidazolidin-4-one (LPSF/NN-52) were obtained by synthesis
as previously described [13] and were authenticated using NMR and IV
spectroscopy and mass spectrometry.
2.3. Experimental animals
MaleMus musculusmice (N=6), provided by the animal facilities
of UFPE, Recife, Brazil, were used for the evaluation of anti-
inﬂammatory and antinociceptive activities of the compounds. The
mice used weighed between 20 and 25 g and were kept in a room
with controlled temperature (22±2 °C) and humidity (50–60%) and
a 12 h/12 h light/dark cycle. Water and food were made available to
the animals without restriction. Before beginning the experiments,
animals were acclimated to the laboratory environment for at least
30 min. All animals used for the determination of anti-inﬂammatory
and antinociceptive activities were fasted for 4 h prior to experimen-
tation. The Animal Studies Committee of the Federal University of
Pernambuco approved the experimental protocols (number
23076.017928/2010-25). The animals were treated according to the
ethical principles of animal experimentation of COBEA (Brazilian
College of Animal Experiments) and the norms of the National
Institute of Health Guide for Care and Use of Laboratory Animals.
2.4. Experimental procedures
2.4.1. Carrageenan-induced air pouch
The anti-inﬂammatory activities of the compounds were tested by
the formation of air pouches on the dorsal cervical region of mice via a
subcutaneous injection of 2.5 mL of sterile air on day 0, followed by a
second injection of 2.5 mL of sterile air 3 days later. On day six, themice received vehicle, indomethacin(10 mg/kg), LPSF/NN-52 or
LPSF/NN-56 (3, 10 or 30 mg/kg) orally. The doses were chosen
according to the results of a pilot experiment and previous work
published by our group using similar compounds [14]. One hour after
drug administration, inﬂammation was induced by injecting 1 mL of
carrageenan suspension (1% in saline solution) into the air pouch.
After 6 h, the animals were euthanized in a CO2 chamber, and the
pouches were washed with 3 mL of saline solution containing 3 μM of
EDTA. A white blood cell count was performed using an ABX Micros 60
hematology analyzer [15]. The average number of leucocytes from the
treated groups was compared with the number of leucocytes of the
control group, which was deﬁned as 100%. The exudates were
centrifuged, and an aliquot of the supernatant was stored at −20 °C
for the analysis of cytokine levels.
2.4.2. Carrageenan-induced peritonitis
Carrageenan-induced peritonitis experiments were performed in
male Swiss mice as previously described [15,16]. The animals received
LPSF/NN-52 and LPSF/NN-56 in 10- and 3-mg/kg doses, respectively.
These doses were chosen because they yielded the best activity in
the air pouch tests. Indomethacin, at a dose of 10 mg/kg, was used as a
positive control and the negative control received vehicle. After
60 min, inﬂammation was induced via the intraperitoneal application
of 0.1 mL/10 g of the phlogistic agent carrageenan (1% in saline). Four
hours after the induction of inﬂammation, the animals were
euthanized in a CO2 chamber, and 2 mL of saline solution containing
3 μM of EDTA was injected into the peritoneal cavity. White blood cell
counts were performed using an ABX Micros 60 hematology analyzer.
The exudates were centrifuged and an aliquot of the supernatant was
stored at −20 °C for the analysis of cytokine levels.
2.4.3. Quantiﬁcation of IL-1β and TNF-α levels
The exudates collected from the air pouch and peritonitis assays
were stored in a freezer at −20 C for the determination of cytokine
levels. Quantiﬁcation of the IL-1β and TNF-α levels in these exudates
was performed by sandwich ELISA using kits that were speciﬁc for
mice according to the manufacturer's instructions (eBioscience, San
Diego, California, USA). The lower detection limit of the assays was
10 pg/mL.
2.4.4. Acetic acid-inducted vascular permeability assays
Vascular permeability assays were performed using the technique
previously described [17] with minor modiﬁcations. The mice were
treated orally with LPSF/NN-52 (10 mg/kg), LPSF/NN-56 (3 mg/kg),
indomethacin (10 mg/kg) or vehicle. One hour after treatment, under
associative anesthesia induced using ketamine/xylazine, Evans blue
dye (1%) was injected into the retro-orbital plexus of the animals
(0.2 mL/animal). Twenty minutes later, 10 mL/kg body weight of 1%
acetic acid in saline was injected intraperitoneally. Twenty minutes
after the injection of acetic acid, the mice were sacriﬁced in a CO2
chamber. After 5 ml of saline was injected into the abdominal cavity,
the washings were collected into test tubes and then centrifuged at
2000 rpm for 10 min. The absorbance of the supernatant was read at
630 nm using an ELISA reader (Thermo plate). The vascular per-
meability was represented in terms of the absorbance (A630) that
leaked into the cavity.
2.4.5. Writhing test
Test animals received LPSF/NN-52 (10 mg/kg), LPSF/NN-56
(3 mg/kg) or diclofenac (30 mg/kg), orally, while the control group
received vehicle only. After an hour, 1% acetic acid was injected
(0.1 mL/10 g) into the peritoneal cavity of the animals. Ten minutes
later, the mice were observed, and the level of writhing during a 20-
minute period was recorded. The percentage inhibition of writhing
was calculated by comparing the average contortions of the treated
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protocol previously described [18] with modiﬁcations.
2.4.6. Formalin test
LPSF/NN-52 (10 mg/kg) and LPSF/NN-56 (3 mg/kg) were orally
administered to animals. One group received fentanyl (200 μg/kg, s.c.),
while a control group received vehicle only. After 15 min, formalin
(20 μL, 2.5%) was injected into the right hind paw of the animals. The
time that the animals spent licking their paws was measured in two
distinct phases 0–5 min (ﬁrst phase) and 15–30 min (second phase)
after the injection of formalin [19,20].
2.4.7. Hot plate test
The mice were placed on an aluminum plate that was heated to a
ﬁxed temperature (55±1 °C). Latency in terms of discomfort re-
actions (i.e., paw licking or jumping) was determined before and after
the administration of drugs. The cut-off time was 20 s. The latency
was recorded before and 30, 60, 120 and 180 min following, oral
administration of LPSF/NN-52 (10 mg/kg), LPSF/NN-56 (3 mg/kg) or
fentanyl (200 μg/Kg, s.c.). The speciﬁc behaviors of the animals, and
their intensities, were recorded according to the methodology
previously described [21].
2.5. Statistical analysis
All results were expressed as mean values±standard deviation for
each experimental group. Statistical analysis between groups was
performed by one-way analysis of variance (ANOVA), followed by the
Bonferroni test. For a conﬁdence interval of 95%, P values less than 0.05
(Pb0.05), as determined usingGraphPad Prism software (version 5.0),
were considered to be indicative of statistical signiﬁcance.
3. Results
3.1. Carrageenan-induced air pouch inﬂammation
The compounds studied exhibited signiﬁcant anti-inﬂammatory
activities and reduced carrageenan-induced cell migration. LPSF/NN-
56 and LPSF/NN-52 were active at doses of 3 mg/kg and 10 mg/kg,
respectively, exhibiting anti-inﬂammatory effects comparable to
indomethacin. There was no statistically signiﬁcant difference
between LPSF/NN-52 (10 mg/kg) and LPSF/NN-56 (3 mg/kg), as
shown in Table 1.
3.2. Quantiﬁcation of IL-1β and TNF-α levels in air pouches
Reductions in the levels of TNF-αwere observed in animals treated
with LPSF/NN-52 (488.32 pg/mL) or LPSF/NN-56 (218.70 pg/mL) in
comparison to the control group (1096.47 pg/mL). For comparison,
indomethacin reduced the concentration of TNFα to 575.43 pg/mL;
thus, LPSF/NN-56 was more effective in reducing TNF-α than
indomethacin. Both compounds also reduced the production of IL-Table 1
Effects of LPSF/NN-52 and LPSF/NN-56 on carrageenan-induced air pouch. *Pb0.05.
Signiﬁcance was determined with ANOVA one way followed by Bonferroni's post hoc
test when compared with control group.
Treated Dose (mg/kg) No. of PMNL/mL (×106) Inhibition %
LPSF/NN-52 3 6.88±1.3* 56.0
10 4.36±0.7* 72.1
30 6.24±0.5* 60.1
LPSF/NN-56 3 3.0±0.7* 80.8
10 5.36±0.6* 65.7
30 6.70±1.3* 57.2
Indomethacin 10 2.08±0.4* 86.7
Control – 15.64±1.9 –1β relative to untreated control values. LPSF/NN-56 was more active
in reducing the production of both cytokines than LPSF/NN-52 (Fig. 1).3.3. Carrageenan-induced peritonitis
The results obtained in the carrageenan-induced peritonitis test
are shown in Table 2. The data revealed that at the doses tested, both
LPSF/NN-52 and LPSF/NN-56 caused a signiﬁcant reduction in the
migration of polymorphonuclear leukocytes in comparison to the
control group. No statistically signiﬁcant difference was observed
between the LPSF/NN-52 (10 mg/kg) and LPSF/NN-56 (3 mg/kg)
treated groups. Indomethacin inhibited cell migration by 57.7%. The
statistical analysis revealed that the indole–imidazolidine derivatives
evaluated exhibited an inhibitory proﬁle similar to indomethacin.3.4. Quantiﬁcation of IL-1β and TNF-α levels in peritonitis
Both LPSF/NN-52 and LPSF/NN-56 promoted a signiﬁcant decrease
in the TNF-α concentration in comparison with the control group.
Both compounds also inhibited the production of IL-1 (Fig. 2).3.5. Acetic acid-induced vascular permeability
The indole–imidazolidine derivatives (LPSF/NN-52 and LPSF/NN-
56) evaluated in this study signiﬁcantly inhibited acetic acid-induced
vascular permeability in comparison to the control group. No
signiﬁcant difference was observed between the derivatives, though
they both exhibited a lower level of inhibition than indomethacin
(Fig. 3).Fig. 1.
Table 2
Effect of LPSF/NN-52 and LPSF/NN-56 on cell migration into peritoneal cavity on
carrageenan-induced peritonitis in mice. The animals received LPSF/NN-52 and
LPSF/NN-56 in 10- and 3-mg/kg doses, respectively. Data are the mean±SD of at
least six animals. *Pb0.05. Signiﬁcance was determined with ANOVA one way followed
by Bonferroni's post hoc test when compared with control group.
Treated Dose (mg/kg) No. of PMNL/mL (x106) Inhibition %
LPSF/NN-52 10 4.80±0.7 * 56.1
LPSF/NN-56 3 4.96±0.9* 54.7
Indomethacin 10 4.62±0.3* 57.7
Control – 10.93±1.6 –
Fig. 3.
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The antinociceptive activities of LPSF/NN-52 and LPSF/NN-56, as
determined using the acetic acid-induced nociception test, are shown
in Table 3. Both LPSF/NN-52 (3 mg/kg) and LPSF/NN-56 (10 mg/kg)
promoted a statistically signiﬁcant reduction in the level of writhing
compared to the control group. The indole–imidazolidine derivative
LSPF/NN-56 exhibited a statistically similar result to standard
diclofenac.3.7. Formalin test
The results shown in Fig. 4 indicate that animals that were treated
orally with LPSF/NN-52 or LPSF/NN-56 signiﬁcantly inhibited forma-
lin-induced pain in comparison to the control group, particularly
during the late phase.Fig. 2.3.8. Hot plate test
The compounds tested showed no activity in treated animals
during any of the time points observed in the hot plate test in
comparison with the control group (Table 4).
4. Discussion
In recent years, molecules containing indole–imidazolidine nuclei
have been identiﬁed as promising drugs for the treatment of in-
ﬂammation and pain [15,22]. In this work, we found that LPSF/NN-56
and LPSF/NN-52 derivatives exhibited promising anti-inﬂammatory
and antinociceptive activities.
The subcutaneous air pouch model, an animal model that mimics
rheumatoid arthritis, is commonly used as a test for screening anti-
arthritic drugs. The air pouch, injected in the back of the animal, forms
a membrane with characteristics similar to the inﬂamed synovium of
patients with rheumatoid arthritis [23]. Both LPSF/NN-52 and
LPSF/NN-56 exhibited signiﬁcant anti-inﬂammatory activity in this
assay, suggesting that these substances may be potential anti-arthritic
drug candidates. Indomethacin, a drug that was used as a positive
control, is a non-steroidal anti-inﬂammatory indole acetic acid de-
rivative that inhibits the activity of the enzyme cyclooxygenase,
decreasing the synthesis of prostaglandins and thromboxane from
arachidonic acid [24]. Air pouch experiments performed by Sayar and
Melli [25] showed that indomethacin is able to reduce leukocyte mi-
gration. According to our results, the compounds that we testedmay be
characterized by a similar mechanism of action; however, further
studies are needed.
The aim of experiments that use the acute peritonitis model is to
evaluate leukocyte migration levels by counting the total number of
leukocytes that are released during the process of acute inﬂammation.
This process occurs after the inoculation of a phlogistic agent via in-
traperitoneal administration. The results of such experiments demon-
strated that both LPSF/NN-52 and LPSF/NN-56 caused signiﬁcantTable 3
Antinociceptive effect of LPSF/NN-52 and LPSF/NN-56 by acetic acid-induced
abdominal constriction. The assay procedure was described in the experimental
methods. Values are expressed mean±S.D. The number of animal used for each group
was six. *Pb0.05. Signiﬁcance was determined with ANOVA one way followed by
Bonferroni's post hoc test when compared with control group.
Treated Dose (mg/kg) No. writhing (mean±SD.) Inhibition %
LPSF/NN-52 10 40.0±3.5⁎ 52.1
LPSF/NN-56 3 30.8±5.9⁎ 63.1
Diclofenac 30 26.8±4.9⁎ 67.9
Control – 83.5±4.8 –
Fig. 4.
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peritoneal cavity. Among the models used in experimental studies, the
induction of neutrophil migration via the intraperitoneal injection of
carrageenan, a substance that stimulates intense chemotactic action, is
commonly used in the investigation of acute inﬂammatory processes
[26]. The mechanism of action bywhich carrageenan induces leukocyte
migration may be a synergism between prostaglandins, leukotriene B4
and other chemotactic agents [27]. It is known that non-steroidal anti-
inﬂammatory drugs, such as indomethacin, which inhibit the synthesis
of vasodilatory prostaglandins, cause a reduction of blood ﬂow that
impairs the migration of polymorphonuclear leukocytes to the sites of
inﬂammation. The results of our tests suggest that the actions of the
indole–imidazolidine derivatives may be related to the inhibition of
cyclooxygenase. Uchôa et al. [15] evaluated a series of indole derivatives
and observed that these substances inhibit COX-1 and, at a lower
potency, COX-2.Table 4
Effects of the LPSF/NN-52 and LPSF/NN-56 on the latency time of mice exposed to the
hot plate test. Each value represents the mean±SD of at least six animals. *Pb0.05.
Signiﬁcance was determined with ANOVA one way followed by Bonferroni's post hoc
test when compared with control group.
Latency time (min.)
Groups (mg/kg) 0 60 120 180
LPSF/NN-52 10 9.2 ±1.8 10.7±0.7 7.12±1.2 8.3±0.5
LPSF/NN-56 3 9.1±0.6 10.6±1.7 11.28±1.7 9.9±0.6
Fentanyl 0.2 9.5±1.7 18.1±0.6* 11.3±0.9* 8.8±1.1
Control – 9.3±0.5 9.7±1.4 8.8±1.3 8.6±1.5To assess the action of the compounds under study in cells of the
innate immune system we determined the concentrations of TNF-α
and IL-1ß in inﬂammatory exudates obtained through air pouch and
peritonitis tests. Our results revealed that both compounds tested
decreased the concentrations of TNF-α and IL-1 β in the inﬂammatory
exudates. TNF-α is a cytokine that plays a key role in the innate
immune response and is associated with reduced cell migration and
exudation [28]. Our results are consistent with a study described by
Yu et al. [29] indicating that hydantoin compounds are potent
inhibitors of the TNF-α precursor enzyme, making the imidazolidine
compounds an attractive target in the search for new anti-inﬂammatory
drugs. IL-1ß promotes the expression of adhesion molecules, leukocyte
migration and increased vascular permeability, indicating that it acts as
an important pro-inﬂammatory mediator [30]. The inhibition of
neutrophil migration observed in our studymay be related to a decrease
in IL-1ß and TNF-α levels. These results suggest that the derivatives
tested in this study act as modulators of the immune system by
decreasing cell migration, exudation and the production of pro-
inﬂammatory cytokines.
Both models of acute inﬂammation used in this study, despite using
the same phlogistic agent, carrageenan, present different cellular
characteristics and cytokine proﬁles. The air pouch model is a valuable
tool to determine the effects of new anti-arthritic drugs, since the air
pouch lining has been reported to display a histological similarity to
synovial membranes [31]. Klenn et al. [32] using the zymosan air pouch
model could reliably measure both humoral and cellular parameters,
with the only exception of the inﬂux of mononuclear leukocytes which
was particularly modest. According to these authors, this lack of
monocyte inﬁltration may be related to the site injected (air pouch vs.
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participation of residents in macrophages peritonitis, recent studies
suggest that peritoneal CD4(+) T lymphocytesmay control recruitment
of polymorphonuclear leukocytes (PMN) during peritonitis by an
interleukin-17 (IL-17)-dependent mechanism. IL-17 and granulocyte
colony-stimulating factor (G-CSF) have been proposed to form an axis
regulating PMN transmigration. Studies have shown that the mesothe-
lium-derived G-CSF plays an important role in IL-17A-induced PMN
recruitment into the peritoneum [33]. In our study substances tested
were more effective in inhibiting IL-1β and TNFα cytokines in the
peritonitis, suggesting that these substances are most promising in this
type of inﬂammation. We suggest that LPSF/NN-52 and LPSF/NN-56
derivatives inhibit the PMN recruitment probably by an interleukin-17
(IL-17)-dependent mechanism. However, a direct effect of LPSF/NN-52
and LPSF/NN-56 on the function of each cellular component in the
inﬂammatory response to carrageenan would be needed to determine
the cellular basis for the anti-inﬂammatory effect of these compounds.
To evaluate the action of indole–imidazolidine derivatives in the
release of vasoactive amines (e.g., histamine, bradykinin and seroto-
nin) and edema formation, we used an acetic acid-induced vascular
permeability test. Both LPSF/NN-52 and LPSF/NN-56 caused a sig-
niﬁcant inhibition of vascular permeability, with reductions of 53.6%
and 49.7%, respectively, compared to control values. Indomethacin
derivatives also reduced acetic acid-induced vascular permeability and
thus have an effect on the ﬁrst phase of the inﬂammatory response by
reducing the action of vasoactive amines.
Acetic acid acts by promoting the release endogenous mediators
that stimulate the nociceptive neurons. In mice, it promotes an
increase in the levels of PGE2, PGF2a, serotonin and histamine and the
release of bradykinin and cytokines such as TNF-α and IL-1β [34,35].
This leads to the occurrence of typical behaviors that are characterized
bywrithing, ataxia and reducedmotor activity. Thus, thismodel allows
us to evaluate inﬂammatory pain and assess whether a molecule has
analgesic and anti-inﬂammatory properties [36]. The results of our
tests indicate that the compounds tested promote a signiﬁcant
reduction in the level of writhing of the control group. In these tests,
both substances exhibited properties similar to diclofenac, which was
used as a positive control.
The induction of painful stimulation via the injection of formalin
occurs in two phases, where the ﬁrst phase (i.e., the ﬁrst 5 min after
injection) is indicative of neurogenic pain and the second phase (i.e.,
15 to 30 min after injection) is indicative of inﬂammatory pain. In
these tests, neither LPSF/NN-52 nor LPSF/NN-56 inhibited pain in the
ﬁrst phase and exhibited activity only in the second phase. Drugs that
act on the ﬁrst phase have central action as narcotics, while drugs that
act on the second phase affect inﬂammatory pain [37]. In our study,
the inhibition of pain in the second phase of the formalin test suggests
a peripheral action similar to NSAID drugs and anti-inﬂammatory
steroids. According to Rosland et al. [38] only inhibition of the second
phase of the formalin test is a typical feature of cyclooxygenase
inhibitors.
In the evaluation of antinociceptive activity via the hot platemethod,
our results revealed that at the analysis times tested, the derivatives
exhibited no action in comparison to the control treatment. The hot
plate test is an animal model used to assess centrally-acting anti-
nociceptive drugs. The behavioral responses exhibitedby animals in this
test (i.e., paw licking or jumping) occur at a supraspinal level; thus, they
are used to investigate the effects of central nociceptives [39]. The
results of these experiments complement those obtained in the acetic
acid-induced writhing tests, allowing us to conclude that the mecha-
nism of action of the compounds tested is not related to central action,
but rather to the ability of the inhibitors to reduce levels of TNF-α and IL-
1, as well as the likely inhibition of prostaglandin production.
Based on the data obtained in this study, we conclude that
imidazolidine derivatives represent promising anti-inﬂammatory and
antinociceptive drug prototypes that act by inhibiting cell migrationin several models of acute inﬂammation and plasma exudation. These
effects may be related to the modulation of the immune system via
reductions in TNF-α and IL-1β concentrations. These compounds act
on inﬂammatory pain and probably have no central effects.Acknowledgments
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